Low-dose rituximab in steroid-refractory chronic graft-versus-host disease
CONCLUSION: A low dose of rituximab is an available and cost-effective option for patients with steroid-refractory cGvHD.PMID:37972876 | DOI:10.1016/j.trim.2023.101959 (Source: Transplant Immunology)
Source: Transplant Immunology - November 16, 2023 Category: Transplant Surgery Authors: Perla Roc ío Colunga-Pedraza Luz Mar ía Barbosa Castillo Edgar Ulises Coronado Alejandro H éctor Alejandro Vaquera-Alfaro Ingrid Gabriela Lopez Reyna Julia E Colunga-Pedraza David G ómez Almaguer Source Type: research
Low-dose rituximab in steroid-refractory chronic graft-versus-host disease
CONCLUSION: A low dose of rituximab is an available and cost-effective option for patients with steroid-refractory cGvHD.PMID:37972876 | DOI:10.1016/j.trim.2023.101959 (Source: Transplant Immunology)
Source: Transplant Immunology - November 16, 2023 Category: Transplant Surgery Authors: Perla Roc ío Colunga-Pedraza Luz Mar ía Barbosa Castillo Edgar Ulises Coronado Alejandro H éctor Alejandro Vaquera-Alfaro Ingrid Gabriela Lopez Reyna Julia E Colunga-Pedraza David G ómez Almaguer Source Type: research
Fallacies of a purely virtual platform: Virtual plus reality versus virtual reality - A case study
We report here a case report where the discrepancy between platforms of testing have raised certain pertinent questions in our interpretation of the vXM.PMID:37952899 | DOI:10.1016/j.trim.2023.101956 (Source: Transplant Immunology)
Source: Transplant Immunology - November 12, 2023 Category: Transplant Surgery Authors: John Gnanaraj Sam Arul Doss S Stephen M Pratheeba Dolly Daniel Source Type: research
Fallacies of a purely virtual platform: Virtual plus reality versus virtual reality - A case study
We report here a case report where the discrepancy between platforms of testing have raised certain pertinent questions in our interpretation of the vXM.PMID:37952899 | DOI:10.1016/j.trim.2023.101956 (Source: Transplant Immunology)
Source: Transplant Immunology - November 12, 2023 Category: Transplant Surgery Authors: John Gnanaraj Sam Arul Doss S Stephen M Pratheeba Dolly Daniel Source Type: research
Fallacies of a purely virtual platform: Virtual plus reality versus virtual reality - A case study
We report here a case report where the discrepancy between platforms of testing have raised certain pertinent questions in our interpretation of the vXM.PMID:37952899 | DOI:10.1016/j.trim.2023.101956 (Source: Transplant Immunology)
Source: Transplant Immunology - November 12, 2023 Category: Transplant Surgery Authors: John Gnanaraj Sam Arul Doss S Stephen M Pratheeba Dolly Daniel Source Type: research
Fallacies of a purely virtual platform: Virtual plus reality versus virtual reality - A case study
We report here a case report where the discrepancy between platforms of testing have raised certain pertinent questions in our interpretation of the vXM.PMID:37952899 | DOI:10.1016/j.trim.2023.101956 (Source: Transplant Immunology)
Source: Transplant Immunology - November 12, 2023 Category: Transplant Surgery Authors: John Gnanaraj Sam Arul Doss S Stephen M Pratheeba Dolly Daniel Source Type: research
Comparative analysis of Basiliximab and Alemtuzumab induction therapies in blood type A2-to-B kidney transplantation: Impact on kidney function and de novo donor-specific HLA antibodies
CONCLUSION: The use of Basiliximab as induction immunosuppression in A2-to-B kidney transplant recipients is associated with a lower incidence of de novo HLA DSA formation without significant differences in overall renal function compared to Alemtuzumab.PMID:37949378 | DOI:10.1016/j.trim.2023.101958 (Source: Transplant Immunology)
Source: Transplant Immunology - November 10, 2023 Category: Transplant Surgery Authors: Tareq Hanouneh Rose Mary Attieh Emily Craver Abdullah Jebrini Mohamed Elrefaei Tambi Jarmi Source Type: research
Comparative analysis of Basiliximab and Alemtuzumab induction therapies in blood type A2-to-B kidney transplantation: Impact on kidney function and de novo donor-specific HLA antibodies
CONCLUSION: The use of Basiliximab as induction immunosuppression in A2-to-B kidney transplant recipients is associated with a lower incidence of de novo HLA DSA formation without significant differences in overall renal function compared to Alemtuzumab.PMID:37949378 | DOI:10.1016/j.trim.2023.101958 (Source: Transplant Immunology)
Source: Transplant Immunology - November 10, 2023 Category: Transplant Surgery Authors: Tareq Hanouneh Rose Mary Attieh Emily Craver Abdullah Jebrini Mohamed Elrefaei Tambi Jarmi Source Type: research
Enrichment of effector memory T cells in the CD4 and CD8 T cell compartment during chronic graft versus host disease in children
CONCLUSION: During chronic GVHD, alloantigen persistence generates TEM cell enrichment among CD4 and CD8 T cells, and viral infections are associated with deficient recovery of T cells after HSCT.PMID:37939887 | DOI:10.1016/j.trim.2023.101951 (Source: Transplant Immunology)
Source: Transplant Immunology - November 8, 2023 Category: Transplant Surgery Authors: Israel Parra-Ortega Noem í Nájera-Martínez F élix Gaytán-Morales Iv án Castorena-Villa Briceida L ópez-Martínez Vianney Ortiz-Navarrete Irlanda Olvera-G ómez Source Type: research
Enrichment of effector memory T cells in the CD4 and CD8 T cell compartment during chronic graft versus host disease in children
CONCLUSION: During chronic GVHD, alloantigen persistence generates TEM cell enrichment among CD4 and CD8 T cells, and viral infections are associated with deficient recovery of T cells after HSCT.PMID:37939887 | DOI:10.1016/j.trim.2023.101951 (Source: Transplant Immunology)
Source: Transplant Immunology - November 8, 2023 Category: Transplant Surgery Authors: Israel Parra-Ortega Noem í Nájera-Martínez F élix Gaytán-Morales Iv án Castorena-Villa Briceida L ópez-Martínez Vianney Ortiz-Navarrete Irlanda Olvera-G ómez Source Type: research
Enrichment of effector memory T cells in the CD4 and CD8 T cell compartment during chronic graft versus host disease in children
CONCLUSION: During chronic GVHD, alloantigen persistence generates TEM cell enrichment among CD4 and CD8 T cells, and viral infections are associated with deficient recovery of T cells after HSCT.PMID:37939887 | DOI:10.1016/j.trim.2023.101951 (Source: Transplant Immunology)
Source: Transplant Immunology - November 8, 2023 Category: Transplant Surgery Authors: Israel Parra-Ortega Noem í Nájera-Martínez F élix Gaytán-Morales Iv án Castorena-Villa Briceida L ópez-Martínez Vianney Ortiz-Navarrete Irlanda Olvera-G ómez Source Type: research
Mesenchymal stem cell-derived exosomes for managing graft-versus-host disease: An updated view
Transpl Immunol. 2023 Nov 5:101957. doi: 10.1016/j.trim.2023.101957. Online ahead of print.ABSTRACTGraft-versus-host disease (GvHD) is the most common complication after stem cell transplantation, and also it is one of the primary limiting factors for the use of hematopoietic stem cell transplantation (HSCT) in the treatment of hematologic cancers. GvHD, a systemic inflammatory disease, is caused by donor T cells recognizing the recipient's foreign antigens. In addition, an immune dysregulation, caused by autoreactive immune cells, complicates potent inflammatory process following HSCT. While there is no one approved treat...
Source: Transplant Immunology - November 7, 2023 Category: Transplant Surgery Authors: Zahra Shafeghat Maryam Dorfaki Shiva Dehrouyeh Fahime Lavi Arab Mona Roozbehani Reza Falak Fatemeh Faraji Reza Jafari Source Type: research
Mesenchymal stem cell-derived exosomes for managing graft-versus-host disease: An updated view
Transpl Immunol. 2023 Nov 5:101957. doi: 10.1016/j.trim.2023.101957. Online ahead of print.ABSTRACTGraft-versus-host disease (GvHD) is the most common complication after stem cell transplantation, and also it is one of the primary limiting factors for the use of hematopoietic stem cell transplantation (HSCT) in the treatment of hematologic cancers. GvHD, a systemic inflammatory disease, is caused by donor T cells recognizing the recipient's foreign antigens. In addition, an immune dysregulation, caused by autoreactive immune cells, complicates potent inflammatory process following HSCT. While there is no one approved treat...
Source: Transplant Immunology - November 7, 2023 Category: Transplant Surgery Authors: Zahra Shafeghat Maryam Dorfaki Shiva Dehrouyeh Fahime Lavi Arab Mona Roozbehani Reza Falak Fatemeh Faraji Reza Jafari Source Type: research
Therapeutic strategies against BK polyomavirus infection in kidney transplant recipients: Systematic review and meta-analysis
CONCLUSIONS: Reducing immunosuppression remains the primary approach for treating BKPyV infection. Although the combination treatment with IVIG proved to be most effective, other agents might offer varied antiviral advantages of high heterogeneity, which should be substantiated in future long-term randomized controlled trials.PMID:37931665 | DOI:10.1016/j.trim.2023.101953 (Source: Transplant Immunology)
Source: Transplant Immunology - November 6, 2023 Category: Transplant Surgery Authors: Cuiyu Zhong Jiayi Chen Ziyan Yan Renfei Xia Wenli Zeng Wenfeng Deng Jian Xu Yuchen Wang Yun Miao Source Type: research
HLA B eplet mismatches in the context of delayed graft function and low tacrolimus trough levels are risk factors influencing the generation of de novo donor-specific antibodies and acute rejection in the early stage after kidney transplantation
CONCLUSIONS: HLA B eplet MM, DGF, and TAC trough levels at 12 months after KT could affect the occurrence of dnDSA and AR in the early stage of KT.PMID:37931666 | DOI:10.1016/j.trim.2023.101955 (Source: Transplant Immunology)
Source: Transplant Immunology - November 6, 2023 Category: Transplant Surgery Authors: Shan Gao Huilin Gong Meihe Li Ping Lan Minyue Zhang Peidan Kuang Ying Zhang Xiaojun Hu Chenguang Ding Yang Li Xiaoming Ding Wujun Xue Jin Zheng Source Type: research
